URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

November 18, 2021

Study Completion Date

July 20, 2022

Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
DRUG

URO-902

intradetrusor injection

DRUG

Placebo

intradetrusor injection

Trial Locations (20)

11530

Accumed Research Associates - ClinEdge - PPDS, Garden City

14225

Great Lakes Physician PC / Western New York Urology Associates, Cheektowaga

18104

Institute For Female Pelvic Medicine, Allentown

21076

Chesapeake Urology Associates, Hanover

23462

Urology of Virginia, Virginia Beach

28078

Urology Specialists of The Carolinas, Huntersville

28203

Atrium Healthcare, Charlotte

33351

Precision Clinical Research LLC, Sunrise

36608

Coastal Clinical Research Inc, Mobile

48073

Beaumont Hospital, Royal Oak

50266

Iowa Clinic, West Des Moines

85715

Urological Associates of Southern Arizona, Tucson

90033

University of Southern California - Norris Hospital, Los Angeles

92562

Tri Valley Urology Medical Group, Murrieta

92653

Orange County Urology Associates, Laguna Hills

94304

Stanford University School of Medicine, Palo Alto

98034

Washington Urology & Urogynecology Associates, Kirkland

02472

Bay State Clinical Trials, Watertown

08837

Premier Urology Group, LLC, Edison

07631

Urology Center of Englewood, Englewood

All Listed Sponsors
lead

Urovant Sciences GmbH

INDUSTRY

NCT04211831 - URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence | Biotech Hunter | Biotech Hunter